Analyst Comment - Clinical Trials Arena https://www.clinicaltrialsarena.com/analyst-comment/ Hard data and deep insights on clinical trials strategy & operations Thu, 07 Nov 2024 17:06:17 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-32x32.png Analyst Comment - Clinical Trials Arena https://www.clinicaltrialsarena.com/analyst-comment/ 32 32 Parkinson’s disease clinical research in 7MM focuses on disease-modifying agents https://www.clinicaltrialsarena.com/analyst-comment/parkinsons-disease-research-7mm/ Thu, 07 Nov 2024 16:45:31 +0000 https://www.clinicaltrialsarena.com/analyst-comment/parkinsons-disease-research-7mm/ Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for Parkinson's disease.

The post Parkinson’s disease clinical research in 7MM focuses on disease-modifying agents appeared first on Clinical Trials Arena.

]]> The post Parkinson’s disease clinical research in 7MM focuses on disease-modifying agents appeared first on Clinical Trials Arena.

]]> Recent popularity of JAK inhibitors in atopic dermatitis https://www.clinicaltrialsarena.com/analyst-comment/jak-inhibitors-atopic-dermatitis-2/ Tue, 05 Nov 2024 16:19:44 +0000 https://www.clinicaltrialsarena.com/analyst-comment/jak-inhibitors-atopic-dermatitis-2/ The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The post Recent popularity of JAK inhibitors in atopic dermatitis appeared first on Clinical Trials Arena.

]]> The post Recent popularity of JAK inhibitors in atopic dermatitis appeared first on Clinical Trials Arena.

]]> Tuberculosis screening efforts successful in vulnerable Canadian province https://www.clinicaltrialsarena.com/analyst-comment/tuberculosis-screening-nunavut-canada/ Tue, 05 Nov 2024 16:08:42 +0000 https://www.clinicaltrialsarena.com/analyst-comment/tuberculosis-screening-nunavut-canada/ The community screening programme charts an effective, affordable framework for TB control in the Canadian province of Nunavut.

The post Tuberculosis screening efforts successful in vulnerable Canadian province appeared first on Clinical Trials Arena.

]]> The post Tuberculosis screening efforts successful in vulnerable Canadian province appeared first on Clinical Trials Arena.

]]> Vaping found to be a risk factor for female infertility https://www.clinicaltrialsarena.com/analyst-comment/vaping-risk-factor-female-infertility/ Mon, 04 Nov 2024 16:11:04 +0000 https://www.clinicaltrialsarena.com/analyst-comment/vaping-risk-factor-female-infertility/ The first week of November is National Fertility Awareness Week in the UK.

The post Vaping found to be a risk factor for female infertility appeared first on Clinical Trials Arena.

]]> The post Vaping found to be a risk factor for female infertility appeared first on Clinical Trials Arena.

]]> IDWeek 2024: the efficacy of SCY-247 in murine models of invasive fungal infections https://www.clinicaltrialsarena.com/analyst-comment/idweek-2024-scy-247-murine-invasive-fungal-infections/ Thu, 31 Oct 2024 09:05:34 +0000 https://www.clinicaltrialsarena.com/analyst-comment/idweek-2024-scy-247-murine-invasive-fungal-infections/

The post IDWeek 2024: the efficacy of SCY-247 in murine models of invasive fungal infections appeared first on Clinical Trials Arena.

]]>

The post IDWeek 2024: the efficacy of SCY-247 in murine models of invasive fungal infections appeared first on Clinical Trials Arena.

]]> Second Alzheimer’s drug rejected by NICE on the same day it is approved in the UK https://www.clinicaltrialsarena.com/analyst-comment/alzheimers-drug-rejection-nice/ Fri, 25 Oct 2024 09:23:18 +0000 https://www.clinicaltrialsarena.com/analyst-comment/alzheimers-drug-rejection-nice/ On 23 October 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly’s anti-amyloid beta (Aβ) monoclonal antibody (mAb) Kisunla for the treatment of patients with mild cognitive impairment (MCI) or mild Alzheimer’s disease in Great Britain.

The post Second Alzheimer’s drug rejected by NICE on the same day it is approved in the UK appeared first on Clinical Trials Arena.

]]> The post Second Alzheimer’s drug rejected by NICE on the same day it is approved in the UK appeared first on Clinical Trials Arena.

]]> IDWeek 2024: highlights on the detection and prevention of NTM outbreaks https://www.clinicaltrialsarena.com/analyst-comment/idweek-2024-highlights-detection-prevention-ntm-outbreaks/ Thu, 24 Oct 2024 14:18:31 +0000 https://www.clinicaltrialsarena.com/analyst-comment/idweek-2024-highlights-detection-prevention-ntm-outbreaks/ During IDWeek 2024, case studies highlighted the current methods for detecting and preventing nontuberculous mycobacteria (NTM) outbreaks.

The post IDWeek 2024: highlights on the detection and prevention of NTM outbreaks appeared first on Clinical Trials Arena.

]]> The post IDWeek 2024: highlights on the detection and prevention of NTM outbreaks appeared first on Clinical Trials Arena.

]]> Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients https://www.clinicaltrialsarena.com/analyst-comment/oral-glp-1-rybelsus-cardiovascular-diabetes/ Wed, 23 Oct 2024 14:20:36 +0000 https://www.clinicaltrialsarena.com/analyst-comment/oral-glp-1-rybelsus-cardiovascular-diabetes/ On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, which is currently approved for T2D.

The post Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients appeared first on Clinical Trials Arena.

]]> The post Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients appeared first on Clinical Trials Arena.

]]> AAO 2024: Brepocitinib achieves treatment failure reductions in NEPTUNE https://www.clinicaltrialsarena.com/analyst-comment/aao-2024-brepocitinib-neptune/ Wed, 23 Oct 2024 13:00:00 +0000 Over the past few days at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, US, the potential of brepocitinib for treating noninfectious intermediate, posterior, and panuveitis was discussed.

The post AAO 2024: Brepocitinib achieves treatment failure reductions in NEPTUNE appeared first on Clinical Trials Arena.

]]> The post AAO 2024: Brepocitinib achieves treatment failure reductions in NEPTUNE appeared first on Clinical Trials Arena.

]]> AAO 2024: Neurodegeneration marker apolipoprotein E is elevated in the serum of patients with glaucoma https://www.clinicaltrialsarena.com/analyst-comment/aao-2024-neurodegeneration-apoe/ Wed, 23 Oct 2024 12:00:00 +0000 On 20 October, during the American Academy of Ophthalmology (AAO) conference in Chicago, US, Hani El Helwe, MD, research fellow in Ophthalmology, Institution Massachusetts Eye and Ear, Infirmary presented findings showing that levels of apolipoprotein E (ApoE) are elevated in the aqueous humour (AH) and serum samples of patients with glaucoma.

The post AAO 2024: Neurodegeneration marker apolipoprotein E is elevated in the serum of patients with glaucoma appeared first on Clinical Trials Arena.

]]> The post AAO 2024: Neurodegeneration marker apolipoprotein E is elevated in the serum of patients with glaucoma appeared first on Clinical Trials Arena.

]]>